Blackstone’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-30,579
Closed -$996K – 666
2026
Q1
$996K Buy
+30,579
New +$1M ﹤0.01% 243
2019
Q3
– Sell
-20,500
Closed -$598K – 91
2019
Q2
$598K Buy
+20,500
New +$550K ﹤0.01% 83

Other funds holding STOK

Blackstone's STOK Position: Q2 2026 in Review

Blackstone sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 30,579 shares — an estimated $996K sold.

Blackstone first reported a position in STOK in Q2 2019 and held it in 2 quarters. The position peaked at $996K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Blackstone reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blackstone sold 30,579 Stoke Therapeutics shares in Q2 2026, an estimated $996K.
  • Blackstone first reported a position in Stoke Therapeutics in Q2 2019 and held it in 2 quarters.
  • Blackstone's Stoke Therapeutics position peaked at $996K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Blackstone's 13F filing for Q2 2026, filed 14 Aug 2026.